PDL BioPharma Inc (PDLI):企業の財務・戦略的SWOT分析

◆英語タイトル:PDL BioPharma Inc (PDLI) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1330
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

PDL BioPharma Inc (PDLI) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions and non-dilutive growth capital to public and private healthcare companies. PDL provides companies, academic institutions and inventors with an immediate financial monetization of royalty streams for acquiring new income generating assets. The company also carries out the humanization of monoclonal antibodies for facilitating the discovery of targeted treatments for cancer and other immunologic diseases. PDL is headquartered in Incline Village, Nevada, the US.

PDL BioPharma Inc Key Recent Developments

Mar 11,2020: PDL BioPharma reports 2019 fourth quarter and full year financial results and announces plan to dissolve the company by year-end 2020
Mar 09,2020: PDL BioPharma announces appointment of Edward A. Imbrogno as vice president and chief financial officer
Feb 28,2020: PDL BioPharma Enters into cooperation agreement with Engine Capital
Dec 23,2019: PDL BioPharma: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
PDL BioPharma Inc – Key Facts
PDL BioPharma Inc – Key Employees
PDL BioPharma Inc – Key Employee Biographies
PDL BioPharma Inc – Major Products and Services
PDL BioPharma Inc – History
PDL BioPharma Inc – Company Statement
PDL BioPharma Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
PDL BioPharma Inc – Business Description
Business Segment: Income Generating Assets
Overview
Performance
Business Segment: Medical Devices
Overview
Performance
Business Segment: Pharmaceutical
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: United States
Performance
PDL BioPharma Inc – Corporate Strategy
PDL BioPharma Inc – SWOT Analysis
SWOT Analysis – Overview
PDL BioPharma Inc – Strengths
PDL BioPharma Inc – Weaknesses
PDL BioPharma Inc – Opportunities
PDL BioPharma Inc – Threats
PDL BioPharma Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
PDL BioPharma Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 11, 2020: PDL BioPharma reports 2019 fourth quarter and full year financial results and announces plan to dissolve the company by year-end 2020
Mar 09, 2020: PDL BioPharma announces appointment of Edward A. Imbrogno as vice president and chief financial officer
Feb 28, 2020: PDL BioPharma Enters into cooperation agreement with Engine Capital
Dec 23, 2019: PDL BioPharma: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers.
Dec 09, 2019: PDL BioPharma announces completion of strategic review process
Nov 06, 2019: PDL BioPharma reports 2019 third quarter financial results
Sep 11, 2019: PDL BioPharma announces favorable decision in Wellstat Diagnostics litigation
Aug 07, 2019: PDL BioPharma reports 2019 second quarter financial results
Jun 25, 2019: PDL BioPharma announces departure of CFO
Jun 24, 2019: Natasha A. Hernday elected to PDL BioPharma’s board of directors
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
PDL BioPharma Inc, Key Facts
PDL BioPharma Inc, Key Employees
PDL BioPharma Inc, Key Employee Biographies
PDL BioPharma Inc, History
PDL BioPharma Inc, Subsidiaries
PDL BioPharma Inc, Key Competitors
PDL BioPharma Inc, Ratios based on current share price
PDL BioPharma Inc, Annual Ratios
PDL BioPharma Inc, Annual Ratios (Cont...1)
PDL BioPharma Inc, Annual Ratios (Cont...2)
PDL BioPharma Inc, Interim Ratios
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
PDL BioPharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
PDL BioPharma Inc, Performance Chart (2015 - 2019)
PDL BioPharma Inc, Ratio Charts
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[PDL BioPharma Inc (PDLI):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Agri-Industries Holdings Ltd (606):企業の財務・戦略的SWOT分析
    China Agri-Industries Holdings Ltd (606) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Enterome Bioscience SA-製薬・医療分野:企業M&A・提携分析
    Summary Enterome Bioscience SA (Enterome) is a drug development company that develops medical tests, and companion diagnostics to develop the management of microbiome-related diseases. The company develops medical tests based on its metagenotype technology platform that helps to identify microbiome- …
  • Power Assets Holdings Ltd (6):石油・ガス:M&Aディール及び事業提携情報
    Summary Power Assets Holdings Limited (Power Assets) a subsidiary of CK Infrastructure Holdings Limited, is an investment holding company. The company through its subsidiaries, joint ventures, and affiliates, invests in power and utility-related businesses. The company has interests in electricity g …
  • Chang Chun Petrochemical Co Ltd:企業の戦略的SWOT分析
    Chang Chun Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • 1414 Degrees Ltd (14D):企業の財務・戦略的SWOT分析
    1414 Degrees Ltd (14D) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Sociedad Minera El Brocal SAA (BROCALC1):企業の財務・戦略的SWOT分析
    Sociedad Minera El Brocal SAA (BROCALC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • CD Diagnostics Inc-医療機器分野:企業M&A・提携分析
    Summary CD Diagnostics Inc (CD Diagnostics), a subsidiary of Zimmer Biomet Holdings Inc is an integrated diagnostics company that develops immunoassays that improve patient outcomes. The company provides synovascure analytical tools. Its products are used in alpha defenses, CRP, hemoglobin tests, in …
  • Crescent Point Energy Corp. (CPG)-石油・ガス分野:企業M&A・提携分析
    Summary Crescent Point Energy Corp. (Crescent Point) is an oil and gas company. It acquires, explores, develops and produces light and medium crude oil, heavy crude oil, tight oil, natural gas liquids, shale gas and conventional natural gas. The company holds interest in light and medium oil and nat …
  • Al Ghubrah Power and Desalination Company:企業の戦略的SWOT分析
    Al Ghubrah Power and Desalination Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Banca Carige SpA (CRG):企業の財務・戦略的SWOT分析
    Banca Carige SpA (CRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • United BioPharma Inc (6471):製薬・医療:M&Aディール及び事業提携情報
    Summary United BioPharma Inc (United BioPharma) is a pharmaceutical company. The company develops, manufactures, and markets monoclonal antibody (mAb) products and biosimilar antibodies. Its molecules product pipeline includes UB-421, a monoclonal antibody for AIDS treatment; and UB-621, an anti-her …
  • Fluidigm Corp (FLDM):医療機器:M&Aディール及び事業提携情報
    Summary Fluidigm Corp (Fluidigm), formerly Mycometrix Corp, develops, manufactures, and markets life science analytical and preparatory systems for mass cytometry, high-throughput genomics, and single-cell genomics markets. The company offers analytical systems and instruments, preparatory instrumen …
  • Spindletop Oil & Gas Co (SPND):石油・ガス:M&Aディール及び事業提携情報
    Summary Spindletop Oil & Gas Co (Spindletop Oil & Gas) is an oil and gas exploration and production company. The company explores, develops and produces crude oil and natural gas in North America. It owns and maintains natural gas pipeline in Texas. Spindletop Oil & Gas also operates various gas pip …
  • Galderma SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Galderma SA (Galderma), a subsidiary of Nestle SA, is a pharmaceutical company that develops and markets drugs, medical dermatology solutions and therapeutic skin care products for the treatment of hair, nail, and skin diseases. Galderma offers products for the treatment of skin conditions s …
  • Great Western Bancorp Inc:企業の戦略・SWOT・財務分析
    Great Western Bancorp Inc - Strategy, SWOT and Corporate Finance Report Summary Great Western Bancorp Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Chemring Ordnance, Inc.:企業の戦略・SWOT・財務情報
    Chemring Ordnance, Inc. - Strategy, SWOT and Corporate Finance Report Summary Chemring Ordnance, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Neuren Pharmaceuticals Ltd (NEU):企業の財務・戦略的SWOT分析
    Summary Neuren Pharmaceuticals Ltd (Neuren Pharma) is a biopharmaceutical company that develops drugs for brain injury, neurodevelopmental and neurodegenerative disorders. The company provides pipeline products such as trofinetide and NNZ-2591. Its trofinetide has a pharmacokinetic profile, which is …
  • Kimball International, Inc. (KBAL):企業の財務・戦略的SWOT分析
    Kimball International, Inc. (KBAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Leggett & Platt Incorporated:企業のM&A・事業提携・投資動向
    Leggett & Platt Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Leggett & Platt Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Transelectrica SA (TEL):企業の財務・戦略的SWOT分析
    Transelectrica SA (TEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆